Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SM70EE is a standardized **70% ethanol extract of Spirulina maxima**, a marine microalga. It is under investigation for its potential cognitive benefits, particularly for improving memory in older adults with **mild cognitive impairment (MCI)**. SM70EE demonstrates antioxidant effects, is thought to mitigate memory loss possibly by reducing hippocampal beta-amyloid (Aβ1-42) accumulation, inhibiting amyloid precursor protein processing, and modulating synaptic and neurotrophic pathways. Clinical trials have reported **statistically significant improvements in visual learning, visual working memory, and vocabulary** in MCI patients over 12 weeks, with an excellent safety profile. Preclinical studies suggest mechanisms involving antioxidative action, acetylcholinesterase inhibition, enhanced brain-derived neurotrophic factor (BDNF), and modulation of neuroinflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SM70EE.